Back to top

Alector Ends GSK Collaboration, Retires Hercules Capital Debt

Alector ( ($ALEC) ) has provided an announcement. On October 21, 2025, Alector reported that its Phase 3 INFRONT-3 trial of latozinemab in frontote...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Alector, Inc. (ALEC)